North Star Asset Management Inc. Has $388,000 Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

North Star Asset Management Inc. increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 127.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 939 shares of the company's stock after purchasing an additional 526 shares during the period. North Star Asset Management Inc.'s holdings in IDEXX Laboratories were worth $388,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in shares of IDEXX Laboratories by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock valued at $948,279,000 after buying an additional 37,734 shares during the last quarter. Bamco Inc. NY grew its holdings in shares of IDEXX Laboratories by 4.3% during the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock worth $829,163,000 after purchasing an additional 82,264 shares in the last quarter. Invesco Ltd. increased its position in shares of IDEXX Laboratories by 6.8% during the fourth quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock valued at $479,999,000 after purchasing an additional 74,324 shares during the period. Norges Bank bought a new stake in shares of IDEXX Laboratories during the fourth quarter valued at approximately $412,258,000. Finally, Northern Trust Corp raised its stake in shares of IDEXX Laboratories by 18.6% in the fourth quarter. Northern Trust Corp now owns 912,874 shares of the company's stock valued at $377,419,000 after purchasing an additional 143,369 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Insider Activity

In related news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the transaction, the director now owns 1,801 shares of the company's stock, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.98% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

IDXX has been the topic of a number of recent research reports. Morgan Stanley lifted their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Bank of America raised their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Barclays upped their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Wall Street Zen upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Finally, Stifel Nicolaus lifted their price objective on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $536.00.

IDEXX Laboratories Stock Down 1.0%

Shares of NASDAQ:IDXX traded down $4.90 during midday trading on Friday, reaching $510.65. 160,236 shares of the company were exchanged, compared to its average volume of 648,967. The firm has a market cap of $41.07 billion, a PE ratio of 47.94, a P/E/G ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $530.60. The stock has a fifty day simple moving average of $447.90 and a two-hundred day simple moving average of $436.67. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.71 earnings per share. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.